Integrin alpha4beta1 Inhibitors
2 drugsAbout Integrin alpha4beta1
Integrin alpha4beta1, or α4β1 integrin, is a cell surface receptor mediating cell adhesion and migration via interactions with the extracellular matrix. As a heterodimeric protein, it influences biological processes, making it a compelling drug target.
Integrin alpha4beta1 is a therapeutic target despite the lack of direct genetic evidence linking it to specific diseases. The existence of two FDA-approved drugs suggests the feasibility of modulating its activity for clinical benefit.
Two FDA-approved drugs target Integrin alpha4beta1: TYRUKO and TYSABRI, developed by Novartis and Biogen, respectively. These drugs include one antibody and one "biologic (other)" modality, used in CNS and other therapeutic areas.
Top Integrin alpha4beta1 Drugs
Novartis and Biogen are the only two companies with approved drugs targeting Integrin alpha4beta1.
The limited number of players indicates a high barrier to entry or untapped market potential.
Integrin alpha4beta1 Drug Modality Landscape
Modalities
Routes of Administration
Integrin alpha4beta1 requires biologic approaches (biologic (other)), likely due to its structure or location.
Exploring small molecule inhibitors could offer a novel approach to targeting Integrin alpha4beta1.
📈 Modality Evolution
Antibodies pioneered Integrin alpha4beta1 targeting (2004), with other biologics entering more recently (2023).
Integrin alpha4beta1 Clinical Trials 36 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Integrin alpha4beta1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 3 | 2 | 0 | 60% |
| Phase 2 | 13 | 10 | 1 | 2 | 91% |
| Phase 3 | 4 | 1 | 3 | 0 | 25% |
| Phase 4 | 14 | 8 | 6 | 0 | 57% |
Top Sponsors
By Modality
Top Conditions
Integrin alpha4beta1 Drug Approval Timeline (2004 - 2023)
The first drug was approved in 2004, with the most recent in 2023, spanning 20 years.
The recent approval suggests renewed interest, but also a potentially saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 15 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Integrin alpha4beta1. A trial counts if an approved drug acting on Integrin alpha4beta1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.